Bioavailability is consistent, dose accuracy is high, and the clinical trial data directly applies
It may be found that BPC 157 participates in ocular control (i.e., BPC 157 counteracted L-NAME-miosis and atropine-mydriasis) (Kokot et al., 2016)
Using cell culture models and molecular analysis techniques including cDNA microarray, RT/real-time PCR, and Western blotting, researchers demonstrated that BPC-157 treatment upregulates GHR expression in a dose- and time-dependent manner at both the mRNA and protein levels
Several human clinical studies have determined the bioavailability of NAC
Putting the Results in Context The improvement seen in the active group (2650% on the investigator scale) over 6 months is encouraging, but context is essential: The improvement level is broadly comparable to other copper peptide studies, though direct comparison is difficult because this study used a categorical improvement scale rather than exact hair counts